Ulotaront hydrochloride by Sumitomo Pharma America for Schizophrenia: Likelihood of Approval

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Schizophrenia.

Dexcom hails CGM share gains as driver of 25% revenue growth in Q2

By the numbers Q2 Revenue: $871.3 million 25% increase year-over-year Q2 Net income: $115.9 million 128% increase year-over-year Q2 Insights Dexcom’s international market share gains

July 28, 2023

Filament Health Announces Issuance of Common Shares to Negev Capital Investments Limited Pursuant to Advisory Agreement | Psychedelic Invest

VANCOUVER, BC, Oct. 4, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today

October 7, 2024

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist – Psychedelic Alpha

Earlier this week, shares in Bright Minds Biosciences (ticker DRUG) rocketed up more than 2,000% and, despite a slight correction over the past two days, are still

October 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.